Publications by authors named "Z Maakaroun-Vermesse"
Background: Cerebral infection with the opportunistic pathogen Bacillus cereus can lead to severe lesions, especially in premature newborns. Early diagnosis would be highly beneficial. The aim of this study was to describe the imaging findings associated with B.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers analyzed data from 361 infants with confirmed pertussis, finding that 32 (9%) developed fulminant symptoms, which were more common in neonates, unvaccinated, and premature infants.
- * Results indicated that B. pertussis strains that produced PRN were associated with higher risks of fulminant pertussis, suggesting the significance of PRN in the severity of the disease.
Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: A French nationwide multicenter cohort study-ANRS0001s COV-POPART.
Int J Infect Dis
September 2024
Background: This study aimed to compare the humoral responses to mRNA COVID-19 vaccination in people living with HIV (PWH) and HIV-negative individuals.
Methods: We included PWH with an undetectable viral load under ART and HIV-negative participants from the French nationwide ANRS COV-POPART cohort who had received two doses of vaccine as a primary vaccination. We compared humoral response between controls and PWH, stratified by CD4 cell count (<200/mm and ≥200/mm CD4 cell counts) at 1, 6, and 12 months after primary vaccination.
Importance: There is still considerable controversy in the literature regarding the capacity of intramuscular messenger RNA (mRNA) vaccination to induce a mucosal immune response.
Objective: To compare serum and salivary IgG and IgA levels among mRNA-vaccinated individuals with or without previous SARS-CoV-2 infection.
Design, Setting, And Participants: In this cohort study, SARS-CoV-2-naive participants and those with previous infection were consecutively included in the CoviCompare P and CoviCompare M mRNA vaccination trials and followed up to day 180 after vaccination with either the BNT162b2 (Pfizer-BioNTech) vaccine or the mRNA-1273 (Moderna) vaccine at the beginning of the COVID-19 vaccination campaign (from February 19 to June 8, 2021) in France.
Article Synopsis
- The ANRS|MIE CoviCompareP study investigated COVID-19 breakthrough infections among vaccinated adults during the Omicron variant's circulation, focusing on those vaccinated with the Pfizer-BioNTech vaccine.
- The study involved healthy adults divided into groups based on previous SARS-CoV-2 infection status and monitored their neutralizing antibodies after vaccination and boosters.
- Results showed that 31% of participants experienced breakthrough infections, with lower infection risks linked to older age, more booster doses, and higher neutralizing antibody levels, especially in those with prior infections.